Eribulin
- Generic Name
- Eribulin
- Brand Names
- Halaven, Eribulin Baxter, Mevlyq
- Drug Type
- Small Molecule
- Chemical Formula
- C40H59NO11
- CAS Number
- 253128-41-5
- Unique Ingredient Identifier
- LR24G6354G
- Background
Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for use in the treatment of advanced solid ...
- Indication
For the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic cancer.
- Associated Conditions
- Metastatic Liposarcoma, Refractory, metastatic Breast cancer, Unresectable Liposarcoma
- Associated Therapies
- -
Eribulin in HER2 Negative Metastatic BrCa
- First Posted Date
- 2013-04-10
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 83
- Registration Number
- NCT01827787
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸DF/BWCC at Milford Regional Cancer Center, Milford, Massachusetts, United States
🇺🇸South Shore Hospital, Weymouth, Massachusetts, United States
A Phase I Dose Escalation Study of Eribulin Plus Weekly Carboplatin for Metastatic Breast Patients
- First Posted Date
- 2013-02-20
- Last Posted Date
- 2022-10-31
- Target Recruit Count
- 19
- Registration Number
- NCT01795586
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-10-12
- Last Posted Date
- 2021-10-06
- Lead Sponsor
- NSABP Foundation Inc
- Target Recruit Count
- 50
- Registration Number
- NCT01705691
- Locations
- 🇺🇸
Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇨🇦Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada
🇨🇦Montreal General Hospital, Montreal, Quebec, Canada
Eribulin Mesylate in Treating Patients With Advanced or Recurrent Cervical Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-08-31
- Last Posted Date
- 2021-11-15
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 32
- Registration Number
- NCT01676818
- Locations
- 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
Pharmacogenomic Study of Neoadjuvant Eribulin for HER2 Non-overexpressing Breast Cancer
- First Posted Date
- 2012-08-20
- Last Posted Date
- 2017-11-06
- Lead Sponsor
- SOLTI Breast Cancer Research Group
- Target Recruit Count
- 163
- Registration Number
- NCT01669252
- Locations
- 🇵🇹
Hospital da Luz, Lisboa, Portugal
🇪🇸Hospital Universitario Virgen de la Arrixaca, Murcia, Spain
🇪🇸Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-06-07
- Last Posted Date
- 2018-09-28
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 29
- Registration Number
- NCT01613768
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer
- First Posted Date
- 2012-05-11
- Last Posted Date
- 2020-07-17
- Lead Sponsor
- Hope Rugo, MD
- Target Recruit Count
- 67
- Registration Number
- NCT01596751
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸Duke University Cancer Center, Durham, North Carolina, United States
🇺🇸Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2
- Conditions
- Interventions
- First Posted Date
- 2012-05-07
- Last Posted Date
- 2021-09-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 54
- Registration Number
- NCT01593020
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of Sorafenib and Eribulin in Combination
- First Posted Date
- 2012-04-26
- Last Posted Date
- 2015-10-27
- Lead Sponsor
- Bayer
- Target Recruit Count
- 40
- Registration Number
- NCT01585870
Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies
- Conditions
- Interventions
- First Posted Date
- 2012-03-15
- Last Posted Date
- 2021-02-03
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 44
- Registration Number
- NCT01554371
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.